A Phase 4 interventional study of Glycopyrronium and SABA in COPD, sponsored by Novartis Pharmaceuticals. Completed at 544 sites in 23 countries. Open to participants aged 40 Years to 95 Years. Per ClinicalTrials.gov, last updated 2019-03-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 3rd largest by enrollment, is one of 9 that started in 2014, is one of 11 in phase 4, and was the 38th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 9 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,389 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one has the largest enrollment of the 116 interventional ones that give a count, is one of 9 that started in 2014, is one of 24 in phase 4, and was the 93rd registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main goal of this study is to evaluate the efficacy and safety of glycopyrronium bromide and indacaterol maleate and glycopyrronium bromide fixed dose combination (FDC) in patients with moderate COPD who switch from their current COPD therapy. This study aims to provide data on how non-exacerbating, but still symptomatic patients with moderate COPD switching from their current COPD treatment to glycopyrronium bromide or indacaterol maleate and glycopyrronium bromide FDC maintain or improve their symptoms. Another purpose of this study is to increase awareness and usage of validated COPD symptoms tools and dyspnea questionnaires in order to facilitate clinical assessment and improve early diagnosis of symptomatic patients.
The treatment epoch will last 12 weeks. The total duration of the study for each patient is 12 weeks (from randomization) plus 30 days of safety follow-up.
The study has three phases: screening phase (=wash-out period, if required), treatment phase and safety follow-up phase.
Eligible patients will be randomized to either receive glycopyrronium or indacaterol maleate and glycopyrronium bromide fixed dose combination or to remain in their baseline therapy, in an allocation ratio of 3:1 for each cluster (Groups A, B, C, and D), based on their COPD symptoms and baseline treatment:
Group A: Patients treated with any SABA ( Short-acting β2-adrenergic agonist) and/or SAMA (Short-acting muscarinic antagonist) as monotherapy or in free or fixed dose combination (FDC) will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) Group B: Patients treated with any LABA (Long-acting β2-adrenergic agonist) or LAMA (Long-acting muscarinic antagonist) monotherapy and mMRC score =1 point will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) Group C: Patients treated with any LABA and ICS (Inhaled corticosteroid) in free or FDC will be assigned to indacaterol maleate and glycopyrronium bromide fixed dose combination or will remain in their baseline therapy (3:1) Group D: Patients treated with any LABA or LAMA monotherapy and mMRC score >1 point will be assigned to indacaterol maleate and glycopyrronium bromide fixed dose combination or will remain in their baseline therapy (3:1) Due to low recruitment in Groups A and B that would lead to a significant delay of trial completion, a protocol amendment was made in order to close the recruitment of Groups A and B at the time the randomization in Groups C and D would be completed. Recruitment of the Groups C and D continued as originally planned
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) during 90 days of treatment
Drug: Glycopyrronium · Drug: SABA · Drug: SAMA
Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)
Drug: Glycopyrronium · Drug: SABA · Drug: LABA · Drug: SAMA
Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA
Drug: LABA · Drug: Indacaterol maleate and glycopyrronium bromide · Drug: LAMA · Drug: ICS
Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)
Drug: LABA · Drug: Indacaterol maleate and glycopyrronium bromide · Drug: LAMA
Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC
Drug: LABA · Drug: ICS
Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)
Drug: LABA · Drug: ICS
Patients treated with any LABA or LAMA monotherapy and mMRC score \>1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA
Drug: LAMA
Patients treated with any LABA or LAMA monotherapy and mMRC score \>1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).
Drug: LAMA
Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
Also known as: glycopyrronium bromide
Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy
Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
Drug pages: Indacaterol maleate · Glycopyrrolate
Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy
Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)
Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval
Time frame: Week 12 (Visit 4)
Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval
Time frame: Week 12 (Visit 4)
Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC
Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.
Time frame: Week 12 (Visit 4)
Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.
Time frame: Week 12 (Visit 4)
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC)
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.
Time frame: Day 1 (baseline) and week 12
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.
Time frame: Day 1 (baseline) and week 12
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.
Time frame: Day 1 (baseline) and week 12
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.
Time frame: Day 1 (baseline) and week 12
Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy)
Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval
Time frame: 12 Weeks
Change From Baseline on on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or Long-acting Bronchodilators (LABA or LAMA Monotherapy)
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.
Time frame: Day 1 (baseline) and week 12
Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC on Trough FEV1 at Week 12.
Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.
Time frame: 12 Weeks
Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.
Time frame: Day 1 (baseline) and week 12
Change From Baseline on Total Score of COPD Assessment Test (CAT) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC
Total score of COPD Assessment Test (CAT) will be measured at baseline and at week 12. This questionnaire is completed by the patient. The score ranges from 0-40 where higher scores represent worse health status. CAT scores ≥ 10 are associated with significantly impaired health status.
Time frame: Day 1 (baseline) and Week 12
Change From Baseline on Total Score of Clinical COPD Questionnaire (CCQ) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC
The Clinical COPD Questionnaire (CCQ) is a self-administered 10-item questionnaire developed to measure clinical control in patients with COPD. Patients will be instructed to recall their experiences during the previous week. They respond to each question using a 7-point scale from 0 = asymptomatic/no imitation to 6 = extremely symptomatic/totally limited. The questionnaire is divided into 3 domains (symptoms \[items 1, 2, 5, and 6\] functional \[items 7, 8, 9, and 10\] and mental state \[items 3 and 4\]). The overall clinical COPD control score and the scores of the domains are calculated by adding all the scores together and dividing this sum by the number of questions. Thus, the overall clinical COPD control score as well as the score on each of the three domains varies between 0 (very good control) to 6 (extremely poor control).
Time frame: Day 1 (baseline) and Week 12
Mean Number of Puffs of Rescue Medication Use for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC
Mean number of puffs of rescue medication use will be measured using eDiary data over 12 weeks of treatment.
Time frame: 12 weeks
Mean Change From Baseline Reported Symptoms of COPD for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC
Patient-reported symptoms of COPD combined will be measured using eDiary data reported over the 12 week treatment period. The mean total symptom scores and mean individual symptom scores for the patient were calculated for the whole study period. The mean change from baseline in the total scores and in the individual scores were summarized by treatment and were analyzed for the percentage of nights with no nighttime awakenings and percentage of days with no symptoms.
Time frame: Baseline, 12 weeks
| Milestone | A1 (Any SABA and/or SAMA) | A2 (Glycopyrronium) | B1 (Any LAMA or LABA and mMRC=1) | B2 (Glycopyrronium and mMRC=1) | C1 (Any LABA and ICS) | C2 (Indacaterol/Glycopyrronium) | D1 (Any LAMA or LABA and mMRC>1) | D2 (Indacaterol/Glycopyrronium and mMRC>1) |
|---|---|---|---|---|---|---|---|---|
| Started | 130 | 387 | 420 | 1262 | 274 | 822 | 274 | 820 |
| The intention-to-treat (itt) population | 122 | 369 | 420 | 1254 | 269 | 811 | 268 | 811 |
| Completed | 107 | 303 | 367 | 1033 | 234 | 666 | 237 | 699 |
| Not completed | 23 | 84 | 53 | 229 | 40 | 156 | 37 | 121 |
| Withdrew: Administrative problems | 1 | 1 | 0 | 2 | 0 | 1 | 1 | 3 |
| Withdrew: Death | 1 | 0 | 0 | 3 | 0 | 0 | 1 | 2 |
| Withdrew: Worsening of disease | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 1 |
| Withdrew: Other | 2 | 9 | 7 | 17 | 4 | 8 | 4 | 7 |
| Withdrew: Protocol deviation | 6 | 31 | 25 | 84 | 17 | 47 | 15 | 42 |
| Withdrew: Moderate / severe copd exacerbation | 5 | 14 | 12 | 40 | 6 | 40 | 8 | 19 |
| Withdrew: Subject withdrawal of consent | 3 | 6 | 2 | 28 | 4 | 19 | 0 | 20 |
| Withdrew: Adverse event | 0 | 8 | 2 | 26 | 3 | 18 | 3 | 15 |
| Withdrew: Other | 4 | 2 | 3 | 10 | 1 | 6 | 2 | 2 |
| Withdrew: Medication non-compliance | 0 | 4 | 1 | 6 | 2 | 3 | 1 | 3 |
| Withdrew: Use of prohibited treatment | 1 | 4 | 1 | 2 | 1 | 6 | 2 | 0 |
| Withdrew: Investigator decision | 0 | 3 | 0 | 7 | 1 | 1 | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 3 | 1 | 4 | 0 | 3 |
Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval
| Liters | A1 (Any SABA and/or SAMA) | A2 (Glycopyrronium) |
|---|---|---|
| Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) | 1.8264 (1.7797 to 1.8732) | 1.8916 (1.8647 to 1.9185) |
Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval
| Liters | B1 (Any LAMA or LABA and mMRC=1) | B2 (Glycopyrronium and mMRC=1) |
|---|---|---|
| Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy) | 1.8004 (1.7768 to 1.8239) | 1.8215 (1.8078 to 1.8352) |
Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.
| Liters | C1 (Any LABA and ICS) | C2 (Indacaterol/Glycopyrronium) |
|---|---|---|
| Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC | 1.6847 (1.6542 to 1.7153) | 1.7558 (1.7378 to 1.7737) |
Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.
| Liters | D1 (Any LAMA or LABA and mMRC>1) | D2 (Indacaterol/Glycopyrronium and mMRC>1) |
|---|---|---|
| Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy) | 1.6728 (1.6461 to 1.6994) | 1.7742 (1.7587 to 1.7896) |
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.
| Units on a scale | A1 (Any SABA and/or SAMA) | A2 (Glycopyrronium) |
|---|---|---|
| Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) | 0.5117 (-0.0073 to 1.0306) | 2.3005 (2.0015 to 2.5995) |
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.
| Units on a scale | B1 (Any LAMA or LABA and mMRC=1) | B2 (Glycopyrronium and mMRC=1) |
|---|---|---|
| Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy) | 0.6969 (0.4169 to 0.9769) | 1.4351 (1.2718 to 1.5984) |
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.
| Units on a scale | C1 (Any LABA and ICS) | C2 (Indacaterol/Glycopyrronium) |
|---|---|---|
| Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA and ICS in Free or FDC | 0.8508 (0.4676 to 1.2340) | 1.9491 (1.7207 to 2.1775) |
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.
| Units on a scale | D1 (Any LAMA or LABA and mMRC>1) | D2 (Indacaterol/Glycopyrronium and mMRC>1) |
|---|---|---|
| Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy) | 0.8632 (0.5098 to 1.2166) | 2.1209 (1.9130 to 2.3288) |
Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval
| Liters | A2 + B2 | A1 + B1 |
|---|---|---|
| Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or vs. Long-acting Bronchodilators (LABA or LAMA Monotherapy) | 1.8373 (1.8250 to 1.8496) | 1.8065 (1.7853 to 1.8276) |
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.
| Score on a scale | A2 +B2 | A1 +B1 |
|---|---|---|
| Change From Baseline on on Transition Dyspnea Index (TDI) for Groups: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) or Long-acting Bronchodilators (LABA or LAMA Monotherapy) | 1.6315 (1.4874 to 1.7756) | 0.6562 (0.4085 to 0.9039) |
Trough FEV1 at visit 4 is defined as FEV1, computed as the mean of forced expiratory volume in 1 second 15min and 45 min pre dose measurements, at the end of the dosing interval.
| Liters | C2 +D2 | C1 + D1 |
|---|---|---|
| Trough FEV1 at Week 12 for Group: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC on Trough FEV1 at Week 12. | 1.7650 (1.7532 to 1.7768) | 1.6789 (1.6587 to 1.6992) |
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.
| Score on a scale | C2 +D2 | C1 + D1 |
|---|---|---|
| Change From Baseline on Transition Dyspnea Index (TDI) for Groups: Indacaterol Maleate and Glycopyrronium Bromide FDC vs. LABA or LAMA Monotherapy or LABA and ICS in Free or FDC | 2.0354 (1.8811 to 2.1896) | 0.8588 (0.5983 to 1.1192) |
Total score of COPD Assessment Test (CAT) will be measured at baseline and at week 12. This questionnaire is completed by the patient. The score ranges from 0-40 where higher scores represent worse health status. CAT scores ≥ 10 are associated with significantly impaired health status.
| Score | A1 (Any SABA and/or SAMA) | A2 (Glycopyrronium) | B1 (Any LAMA or LABA and mMRC=1) | B2 (Glycopyrronium and mMRC=1) | C1 (Any LABA and ICS) | C2 (Indacaterol/Glycopyrronium) | D1 (Any LAMA or LABA and mMRC>1) | D2 (Indacaterol/Glycopyrronium and mMRC>1) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline on Total Score of COPD Assessment Test (CAT) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC | 0.1 ± 4.6 | -1.8 ± 5.3 | 0.1 ± 4.9 | -0.5 ± 4.6 | -0.4 ± 4.8 | -1.4 ± 5.4 | -0.9 ± 5.0 | -1.9 ± 5.3 |
The Clinical COPD Questionnaire (CCQ) is a self-administered 10-item questionnaire developed to measure clinical control in patients with COPD. Patients will be instructed to recall their experiences during the previous week. They respond to each question using a 7-point scale from 0 = asymptomatic/no imitation to 6 = extremely symptomatic/totally limited. The questionnaire is divided into 3 domains (symptoms \[items 1, 2, 5, and 6\] functional \[items 7, 8, 9, and 10\] and mental state \[items 3 and 4\]). The overall clinical COPD control score and the scores of the domains are calculated by adding all the scores together and dividing this sum by the number of questions. Thus, the overall clinical COPD control score as well as the score on each of the three domains varies between 0 (very good control) to 6 (extremely poor control).
| Score | A1 (Any SABA and/or SAMA) | A2 (Glycopyrronium) | B1 (Any LAMA or LABA and mMRC=1) | B2 (Glycopyrronium and mMRC=1) | C1 (Any LABA and ICS) | C2 (Indacaterol/Glycopyrronium) | D1 (Any LAMA or LABA and mMRC>1) | D2 (Indacaterol/Glycopyrronium and mMRC>1) |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline on Total Score of Clinical COPD Questionnaire (CCQ) for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC | -0.0 ± 0.6 | -0.3 ± 0.7 | 0.0 ± 0.7 | -0.1 ± 0.7 | -0.1 ± 0.7 | -0.2 ± 0.8 | -0.1 ± 0.8 | -0.3 ± 0.8 |
Mean number of puffs of rescue medication use will be measured using eDiary data over 12 weeks of treatment.
| Number of puffs | A1 (Any SABA and/or SAMA) | A2 (Glycopyrronium) | B1 (Any LAMA or LABA and mMRC=1) | B2 (Glycopyrronium and mMRC=1) | C1 (Any LABA and ICS) | C2 (Indacaterol/Glycopyrronium) | D1 (Any LAMA or LABA and mMRC>1) | D2 (Indacaterol/Glycopyrronium and mMRC>1) |
|---|---|---|---|---|---|---|---|---|
| Mean Number of Puffs of Rescue Medication Use for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC | 1.8 ± 1.7 | 1.0 ± 1.3 | 0.8 ± 1.2 | 0.7 ± 1.1 | 1.6 ± 1.7 | 1.1 ± 1.4 | 1.4 ± 1.4 | 1.1 ± 1.3 |
Patient-reported symptoms of COPD combined will be measured using eDiary data reported over the 12 week treatment period. The mean total symptom scores and mean individual symptom scores for the patient were calculated for the whole study period. The mean change from baseline in the total scores and in the individual scores were summarized by treatment and were analyzed for the percentage of nights with no nighttime awakenings and percentage of days with no symptoms.
| Percentage of days | A1 (Any SABA and/or SAMA) | A2 (Glycopyrronium) | B1 (Any LAMA or LABA and mMRC=1) | B2 (Glycopyrronium and mMRC=1) | C1 (Any LABA and ICS) | C2 (Indacaterol/Glycopyrronium) | D1 (Any LAMA or LABA and mMRC>1) | D2 (Indacaterol/Glycopyrronium and mMRC>1) |
|---|---|---|---|---|---|---|---|---|
| Mean Change From Baseline Reported Symptoms of COPD for Groups: Glycopyrronium and Indacaterol Maleate and Glycopyrronium Bromide FDC | -0.04 ± 0.15 | -0.10 ± 0.22 | -0.03 ± 0.19 | -0.05 ± 0.20 | -0.05 ± 0.19 | -0.07 ± 0.22 | -0.04 ± 0.19 | -0.09 ± 0.21 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A1 (Any SABA and/or SAMA) | — | 4/125 (3.2%) | 19/125 (15.2%) |
| A2 (Glycopyrronium) | — | 9/385 (2.3%) | 67/385 (17.4%) |
| B1 (Any LAMA or@ LABA and mMRC eq 1) | — | 11/417 (2.6%) | 63/417 (15.1%) |
| B2 (Glycopyrronium@ and mMRC eq 1) | — | 30/1,248 (2.4%) | 163/1,248 (13.1%) |
| C1 (Any LABA and ICS) | — | 6/269 (2.2%) | 29/269 (10.8%) |
| C2 (Indacaterol/@Glycopyrronium) | — | 22/816 (2.7%) | 119/816 (14.6%) |
| D1 (Any LAMA or@ LABA and mMRC gt 1) | — | 10/269 (3.7%) | 20/269 (7.4%) |
| D2 (Indacaterol/@Glycopyrronium and@ mMRC gt 1) | — | 34/814 (4.2%) | 120/814 (14.7%) |
| Event | A1 (Any SABA and/or SAMA) | A2 (Glycopyrronium) | B1 (Any LAMA or@ LABA and mMRC eq 1) | B2 (Glycopyrronium@ and mMRC eq 1) | C1 (Any LABA and ICS) | C2 (Indacaterol/@Glycopyrronium) | D1 (Any LAMA or@ LABA and mMRC gt 1) | D2 (Indacaterol/@Glycopyrronium and@ mMRC gt 1) |
|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/125 | 1/385 | 0/417 | 2/1248 | 0/269 | 1/816 | 1/269 | 7/814 |
| Cardiac arrestCardiac disorders | 1/125 | 0/385 | 0/417 | 0/1248 | 0/269 | 0/816 | 0/269 | 0/814 |
| Myocardial infarctionCardiac disorders | 1/125 | 0/385 | 0/417 | 1/1248 | 0/269 | 0/816 | 1/269 | 1/814 |
| HydroceleCongenital, familial and genetic disorders | 1/125 | 0/385 | 0/417 | 0/1248 | 0/269 | 0/816 | 0/269 | 0/814 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/125 | 0/385 | 0/417 | 1/1248 | 0/269 | 0/816 | 0/269 | 0/814 |
| Transient ischaemic attackNervous system disorders | 1/125 | 0/385 | 0/417 | 0/1248 | 0/269 | 0/816 | 0/269 | 0/814 |
| Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders | 1/125 | 0/385 | 0/417 | 0/1248 | 0/269 | 0/816 | 0/269 | 0/814 |
| Coronary artery diseaseCardiac disorders | 0/125 | 2/385 | 1/417 | 0/1248 | 0/269 | 0/816 | 0/269 | 0/814 |
| Angina unstableCardiac disorders | 0/125 | 0/385 | 0/417 | 0/1248 | 0/269 | 0/816 | 1/269 | 0/814 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/125 | 0/385 | 0/417 | 0/1248 | 1/269 | 0/816 | 0/269 | 0/814 |
| Event | A1 (Any SABA and/or SAMA) | A2 (Glycopyrronium) | B1 (Any LAMA or@ LABA and mMRC eq 1) | B2 (Glycopyrronium@ and mMRC eq 1) | C1 (Any LABA and ICS) | C2 (Indacaterol/@Glycopyrronium) | D1 (Any LAMA or@ LABA and mMRC gt 1) | D2 (Indacaterol/@Glycopyrronium and@ mMRC gt 1) |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/125 | 38/385 | 24/417 | 71/1248 | 11/269 | 37/816 | 10/269 | 54/814 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/125 | 5/385 | 13/417 | 33/1248 | 5/269 | 44/816 | 4/269 | 27/814 |
| PharyngitisInfections and infestations | 3/125 | 1/385 | 0/417 | 7/1248 | 0/269 | 3/816 | 1/269 | 5/814 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/125 | 5/385 | 6/417 | 13/1248 | 6/269 | 7/816 | 2/269 | 7/814 |
| HeadacheNervous system disorders | 0/125 | 7/385 | 3/417 | 9/1248 | 1/269 | 12/816 | 1/269 | 8/814 |
| RhinitisInfections and infestations | 0/125 | 1/385 | 7/417 | 12/1248 | 2/269 | 5/816 | 1/269 | 10/814 |
| HypertensionVascular disorders | 1/125 | 3/385 | 7/417 | 7/1248 | 2/269 | 5/816 | 0/269 | 7/814 |
| DyspepsiaGastrointestinal disorders | 2/125 | 0/385 | 1/417 | 3/1248 | 0/269 | 2/816 | 0/269 | 1/814 |
| TracheitisInfections and infestations | 2/125 | 0/385 | 2/417 | 2/1248 | 0/269 | 2/816 | 0/269 | 2/814 |
| Urinary tract infectionInfections and infestations | 2/125 | 2/385 | 1/417 | 5/1248 | 0/269 | 1/816 | 0/269 | 3/814 |
| Age, Continuous(Years) | A1 (Any SABA and/or SAMA) | A2 (Glycopyrronium) | B1 (Any LAMA or LABA and mMRC=1) | B2 (Glycopyrronium and mMRC=1) | C1 (Any LABA and ICS) | C2 (Indacaterol/Glycopyrronium) | D1 (Any LAMA or LABA and mMRC>1) | D2 (Indacaterol/Glycopyrronium and mMRC>1) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 64.2 ± 8.2 | 63.2 ± 8.3 | 64.6 ± 8.1 | 64.4 ± 8.2 | 64.4 ± 9.0 | 64.7 ± 8.7 | 65.1 ± 7.6 | 65.4 ± 8.3 | 64.6 ± 8.3 |
| Sex: Female, Male(Participants) | A1 (Any SABA and/or SAMA) | A2 (Glycopyrronium) | B1 (Any LAMA or LABA and mMRC=1) | B2 (Glycopyrronium and mMRC=1) | C1 (Any LABA and ICS) | C2 (Indacaterol/Glycopyrronium) | D1 (Any LAMA or LABA and mMRC>1) | D2 (Indacaterol/Glycopyrronium and mMRC>1) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 48 | 119 | 131 | 376 | 106 | 286 | 95 | 276 | 1437 |
| Male | 82 | 268 | 289 | 886 | 168 | 536 | 179 | 544 | 2952 |
Showing the first 100 of 544 sites across 23 countries. Choose a country and city above to see the rest.
Ran from Feb 2014 to primary completion in Apr 2016, 26 months.
Results were first posted in Mar 2019, 2 years 10 months after primary completion.
Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 26 months is above that.
Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Glycopyrrolate · Indacaterol maleate
Pulmonary Disease, Chronic Obstructive →